• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards | Inspections
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
Trade NameCONTINUOUS SUBCUTANEOUS GLUCOSE MONITORING SYSTEM
Classification Namesensor, glucose, invasive
Generic Namecontinuous subcutaneous glucose monitoring system
ApplicantMEDTRONIC MINIMED
PMA NumberP980022
Supplement NumberS024
Date Received12/17/2007
Decision Date02/08/2008
Product Code
MDS[ Registered Establishments with MDS ]
Advisory Committee Clinical Chemistry
Supplement Typereal-time process
Supplement Reason design change - minor
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for software modifications, a design change to the paradigm real-time pump (model mmt-522, 722), and a change to the storage and shipping temperature of the glucose sensor (mmt-7002c, d, e). Software modifications included updating the guardian real-time monitor (css7100) software to version 2. 0a and updating the carelink online (mmt-7333) software to version 4. 1. The design change to the paradigm real time pump involves a redesign of the motor flex assembly to increase durability of the flexprint connector. The change to the glucose sensor shipping and storage conditions includes an expansion of the temperature range to 2-27 degrees c and allows warehouse-to-customer shipping at non-refrigerated temperatures. This device is intended to continuously record interstitial glucose levels in persons with diabetes mellitus. This information is intended to supplement, not replace, blood glucose information obtained using a standard home glucose-monitoring devices. This information may allow identification of patterns of glucose level excursions above or below the desired range, facilitating therapy adjustments which may minimize these excursions.
-
-